LIN Stock Analysis: Linde Ordinary Shares | NASDAQ
Specialty Chemicals | NASDAQ, USA | Market Cap: 225.857m USD | 12M Return: 4.3% | IE000S9YS762 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 981M
EPS Trend: 99.6%
Qual. Beats: 0
Rev. Trend: 88.9%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Linde plc is a global industrial gas company headquartered in the United Kingdom and founded in 1879. It produces atmospheric gases such as oxygen, nitrogen, and argon, as well as process gases including hydrogen, helium, carbon dioxide, and specialty gases. Beyond gas production, Linde designs and constructs turnkey process plants, such as air separation and hydrogen facilities, for both internal operations and third-party customers. Its products serve a broad range of end-markets, including healthcare, chemicals and energy, manufacturing, metals and mining, food and beverage, and electronics, with operations spanning the Americas, Europe, and Asia-Pacific.
The industrial gases sector is defined by high capital intensity and significant barriers to entry, as production facilities such as air separation units require substantial upfront investment and are typically supported by long-term supply agreements with customers. Linde trades on NASDAQ under the ticker LIN and is classified within the Materials sector as a mega-cap stock. The company was formed following the 2018 merger of Germanys Linde AG and U.S.-based Praxair, creating the worlds largest industrial gases business by revenue.
- Hydrogen project backlog expands across clean energy initiatives
- Industrial gas pricing benefits from sustained merchant volume growth
- Backlog strength in electronics gases supports margin expansion
| Net Income: 7.24b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.26 > 1.0 |
| NWC/Revenue: -5.50% < 20% (prev -3.27%; Δ -2.23% < -1%) |
| CFO/TA 0.12 > 3% & CFO 10.5b > Net Income 7.24b |
| Net Debt (24.2b) to EBITDA (13.4b): 1.80 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (464.5m) vs 12m ago -1.91% < -2% |
| Gross Margin: 37.56% > 18% (prev 37.24%; Δ 0.32% > 0.5%) |
| Asset Turnover: 40.65% > 50% (prev 38.62%; Δ 2.02% > 0%) |
| Interest Coverage Ratio: 35.85 > 6 (EBIT TTM 9.61b / Interest Expense TTM 268.0m) |
| A: -0.02 (Total Current Assets 14.2b - Total Current Liabilities 16.1b) / Total Assets 88.3b |
| B: 0.21 (Retained Earnings 18.8b / Total Assets 88.3b) |
| C: 0.11 (EBIT TTM 9.61b / Avg Total Assets 87.2b) |
| D: 0.82 (Book Value of Equity 39.1b / Total Liabilities 47.7b) |
| Altman-Z'' = 2.15 = BBB |
| DSRI: 1.04 (Receivables 6.06b/5.49b, Revenue 35.4b/33.2b) |
| GMI: 0.99 (GM 37.24% / 37.56%) |
| AQI: 0.96 (AQ_t 0.51 / AQ_t-1 0.53) |
| SGI: 1.07 (Revenue 35.4b / 33.2b) |
| TATA: -0.04 (NI 7.24b - CFO 10.5b) / TA 88.3b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of October 08, 2026, the stock is trading at USD 483.98 with a total of 1,940,149 shares traded. Over the past week, the price has changed by +1.97%, over one month by +3.33%, over three months by -9.78% and over the past year by +4.29%.
Current recommended Stop Loss: 472.30 (which is 2.4% or 1.4 ATR below the current price).
Linde Ordinary Shares has received a consensus analysts rating of 4.32. Therefore, it is recommended to buy LIN.
- StrongBuy: 17
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 543.8 | 12.4% |
P/E Trailing = 31.1475
P/E Forward = 23.5849
P/S = 6.3713
P/B = 5.4838
P/EG = 1.7997
Revenue TTM = 35.4b USD
EBIT TTM = 9.61b USD
EBITDA TTM = 13.4b USD
Long Term Debt = 20.7b USD (from longTermDebt, last quarter)
Short Term Debt = 7.33b USD (from shortTermDebt, last quarter)
Debt = 29.1b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.08b
Net Debt = 24.2b USD (calculated: Debt 29.1b - CCE 4.90b)
Enterprise Value = 250b USD (226b + Debt 29.1b - CCE 4.90b)
Interest Coverage Ratio = 35.85 (Ebit TTM 9.61b / Interest Expense TTM 268.0m)
EV/FCF = 50.26x (Enterprise Value 250b / FCF TTM 4.97b)
FCF Yield = 1.99% (FCF TTM 4.97b / Enterprise Value 250b)
FCF Margin = 14.03% (FCF TTM 4.97b / Revenue TTM 35.4b)
Net Margin = 20.43% (Net Income TTM 7.24b / Revenue TTM 35.4b)
Gross Margin = 37.56% ((Revenue TTM 35.4b - Cost of Revenue TTM 22.1b) / Revenue TTM)
Gross Margin QoQ = 37.30% (prev 37.66%)
Tobins Q-Ratio = 2.83 (Enterprise Value 250b / Total Assets 88.3b)
Interest Expense / Debt = 0.92% (Interest Expense 268.0m / Debt 29.1b)
Taxrate = 21.95% (2.09b / 9.50b)
NOPAT = 7.50b (EBIT 9.61b * (1 - 21.95%))
Current Ratio = 0.88 (Total Current Assets 14.2b / Total Current Liabilities 16.1b)
Debt / Equity = 0.74 (Debt 29.1b / totalStockholderEquity, last quarter 39.1b)
Debt / EBITDA = 1.80 (Net Debt 24.2b / EBITDA 13.4b)
Debt / FCF = 4.86 (Net Debt 24.2b / FCF TTM 4.97b)
Total Stockholder Equity = 38.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.31% (Net Income 7.24b / Total Assets 88.3b)
RoE = 18.75% (Net Income TTM 7.24b / Total Stockholder Equity 38.6b)
RoCE = 16.20% (EBIT 9.61b / Capital Employed (Equity 38.6b + L.T.Debt 20.7b))
RoIC = 9.64% (NOPAT 7.50b / Invested Capital 77.8b)
WACC = 5.94% (E(226b)/V(255b) * Re(6.61%) + D(29.1b)/V(255b) * Rd(0.92%) * (1-Tc(0.22)))
Discount Rate = 6.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.95 | Cagr: -1.95%
[DCF] Terminal Value 75.19% ; FCFF base≈5.01b ; Y1≈4.96b ; Y5≈5.09b
[DCF] Fair Price = 119.8 (EV 79.4b - Net Debt 24.2b = Equity 55.2b / Shares 461.0m; r=8.35% [WACC [floored]]; 5y FCF grow -1.85% → 2.50% )
EPS Correlation: 99.63 | EPS CAGR: 7.96% | SUE: 0.64 | # QB: 0
Revenue Correlation: 88.94 | Revenue CAGR: 2.60% | SUE: 1.93 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=-25% | Analysts=19
EPS current Year (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=+29% | GrowthEPS=+8.6% | GrowthRev=+6.9%
EPS next Year (2027-12-31): EPS=18.21 | Chg30d=-0.39% | Revisions=+0% | GrowthEPS=+11.1% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: +10% (up=4, down=3)